New BRCA2 Mutation Linked to Breast Cancer
Author Information
Author(s): Hansen Thomas V O, Bisgaard Marie Luise, Jønson Lars, Albrechtsen Anders, Filtenborg-Barnkob Bettina, Eiberg Hans, Ejlertsen Bent, Nielsen Finn C
Primary Institution: Rigshospitalet, Copenhagen, Denmark
Hypothesis
Is the novel BRCA2 splice site mutation a de novo mutation that contributes to breast cancer risk?
Conclusion
The identified BRCA2 splice variant is a de novo mutation that leads to a truncated BRCA2 protein and is classified as disease-causing.
Supporting Evidence
- The mutation was identified in a patient with a ductal carcinoma at age 40.
- The mutation activates a cryptic splice site, leading to a truncated BRCA2 protein.
- The mutation was not found in the patient's parents, confirming its de novo status.
Takeaway
A woman with breast cancer had a new mutation in a gene called BRCA2 that she didn't inherit from her parents, meaning it just happened in her.
Methodology
The study involved genetic screening of BRCA1 and BRCA2 genes using dHPLC and sequencing, along with functional characterization of the mutation through exon trapping and RT-PCR.
Limitations
The study did not obtain ethical approval as it was part of normal diagnostic procedures.
Participant Demographics
The study focused on a 40-year-old woman with a family history of breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website